Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Bacteria can fend off viral infections by chopping up their DNA with their CRISPR-based immune system ... and this has important implications for using phage to treat human infections, since the dose ...

Bring up germline editing, and most scientists cringe. The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos tinkers with DNA far beyond just the patient—any changes ...

The researchers use a trick to do this: in addition to the CRISPR sequence, they introduce a so-called phage promoter into the cellular genome, which amplifies the CRISPR sequences and makes them ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Learn about our Editorial Policies. We can target harmful bacteria. We can engineer beneficial bacteria. We can use CRISPR to study microbial interactions. We can use CRISPR to remove antibiotic ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Efficient and site-specific genome engineering can be achieved based on programmable nucleic acid cleavage using CRISPR-Cas surveillance complexes. Structure-function studies on single component Cas ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...